Posted inClinical Updates Oncology Specialties
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous-Cell Carcinoma: A Review of Recent Evidence and Clinical Implications
Adjuvant cemiplimab significantly improves disease-free survival in patients with high-risk cutaneous squamous-cell carcinoma post-surgery and radiotherapy, reducing locoregional and distant recurrences compared to placebo, with manageable toxicity.